Vivoryon issues updates on its Alzheimer’s therapy programme
The complete data readouts of two-Phase II trials are expected in 2024, with an additional open-label extension study currently in the works.
The complete data readouts of two-Phase II trials are expected in 2024, with an additional open-label extension study currently in the works.
What's Your Reaction?
